Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on developing treatments for neurodegenerative diseases, has appointed Abby Macnish Niven as its new Chief Financial Officer (CFO), effective immediately. CEO David Stamler expressed confidence in Ms Macnish Niven's broad experience and financial background to help advance the company's programs.
Ms Macnish Niven brings extensive experience in private wealth management from groups including ANZ, UBS, and Ord Minett. She also consults for various listed and unlisted companies in governance, finance, and corporate structure. She holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia and is a Chartered Finance Analyst.
Ms Macnish Niven replaces Mr Phillip Hains, who served as CFO since December 2023. Mr Hains will continue as Company Secretary.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), una società biotecnologica focalizzata nello sviluppo di trattamenti per le malattie neurodegenerative, ha nominato Abby Macnish Niven come nuovo Chief Financial Officer (CFO), con effetto immediato. Il CEO David Stamler ha espresso fiducia nell'ampia esperienza e nel background finanziario della signora Macnish Niven per aiutare a portare avanti i programmi dell'azienda.
La signora Macnish Niven porta con sé una vasta esperienza nella gestione patrimoniale privata proveniente da gruppi come ANZ, UBS e Ord Minett. Consulente per diverse aziende quotate e non quotate in governance, finanza e struttura aziendale, ha conseguito una laurea in Commercio e una laurea in Scienze presso l'Università dell'Australia Occidentale ed è una Chartered Finance Analyst.
La signora Macnish Niven sostituisce il signor Phillip Hains, che ha ricoperto il ruolo di CFO da dicembre 2023. Il signor Hains continuerà come Segretario Aziendale.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), una empresa biotecnológica centrada en desarrollar tratamientos para enfermedades neurodegenerativas, ha nombrado a Abby Macnish Niven como su nuevo Director Financiero (CFO), con efecto inmediato. El CEO David Stamler expresó confianza en la amplia experiencia y el historial financiero de la Sra. Macnish Niven para ayudar a avanzar en los programas de la empresa.
La Sra. Macnish Niven aporta una amplia experiencia en gestión de patrimonio privado de grupos como ANZ, UBS y Ord Minett. También asesora a varias empresas cotizadas y no cotizadas en gobernanza, finanzas y estructura corporativa. Tiene títulos en Comercio y Ciencias de la Universidad de Australia Occidental y es Analista Financiero Certificado.
La Sra. Macnish Niven reemplaza al Sr. Phillip Hains, quien se desempeñó como CFO desde diciembre de 2023. El Sr. Hains continuará como Secretario de la Empresa.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)는 신경퇴행성 질환 치료법 개발에 중점을 둔 바이오테크 기업으로서 Abby Macnish Niven을 새로운 최고재무책임자(CFO)로 즉시 임명했습니다. CEO David Stamler는 Ms. Macnish Niven의 폭넓은 경험과 재무 배경이 회사의 프로그램을 발전시키는데 도움이 될 것이라고 확신했습니다.
Ms. Macnish Niven은 ANZ, UBS 및 Ord Minett와 같은 그룹에서 자산 관리에 대한 풍부한 경험을 가지고 있습니다. 그녀는 또한 여러 상장 및 비상장 기업의 거버넌스, 재무 및 기업 구조에 대해 컨설팅을 진행합니다. 그녀는 웨스턴오스트레일리아대학교에서 상업학과 과학학사 학위를 취득했으며, 공인재무분석사입니다.
Ms. Macnish Niven은 2023년 12월부터 CFO 역할을 수행해온 Mr. Phillip Hains를 교체합니다. Hains씨는 회사 비서로 계속 활동할 것입니다.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), une entreprise biotechnologique axée sur le développement de traitements pour les maladies neurodégénératives, a nommé Abby Macnish Niven en tant que nouveau Directeur Financier (CFO), avec effet immédiat. Le PDG David Stamler a exprimé sa confiance dans l'expérience variée et le parcours financier de Mme Macnish Niven pour aider à faire avancer les programmes de l'entreprise.
Mme Macnish Niven apporte une expérience considérable en gestion de patrimoine privé venant de groupes tels qu'ANZ, UBS et Ord Minett. Elle consulte également pour diverses sociétés cotées et non cotées en matière de gouvernance, de finance et de structure d'entreprise. Elle détient un Bachelor en commerce et un Bachelor en sciences de l'Université d'Australie-Occidentale et est Analyste Financier Certifié.
Mme Macnish Niven remplace M. Phillip Hains, qui a été CFO depuis décembre 2023. M. Hains continuera en tant que secrétaire de l'entreprise.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), ein auf die Entwicklung von Therapien für neurodegenerative Erkrankungen fokussiertes Biotechnologieunternehmen, hat Abby Macnish Niven mit sofortiger Wirkung zur neuen Chief Financial Officer (CFO) ernannt. CEO David Stamler äußerte Vertrauen in die breite Erfahrung und den finanziellen Hintergrund von Frau Macnish Niven, um die Programme des Unternehmens voranzubringen.
Frau Macnish Niven bringt umfassende Erfahrungen in der Vermögensverwaltung aus Gruppen wie ANZ, UBS und Ord Minett mit. Sie berät auch verschiedene börsennotierte und nicht börsennotierte Unternehmen in den Bereichen Governance, Finanzen und Unternehmensstruktur. Sie hat einen Bachelor-Abschluss in Betriebswirtschaft und einen Bachelor-Abschluss in Wissenschaft von der University of Western Australia und ist Chartered Financial Analyst.
Frau Macnish Niven ersetzt Herrn Phillip Hains, der seit Dezember 2023 CFO war. Herr Hains wird weiterhin als Unternehmenssekretär tätig sein.
- Appointment of a new CFO with extensive financial experience
- New CFO has a background in private wealth management and corporate consulting
- Continuity in company leadership with the former CFO remaining as Company Secretary
- None.
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company’s Chief Financial Officer (CFO), effective today.
“We look forward to Abby’s contributions whose broad experience and financial background will help us advance our programs. I would also like to express my gratitude to Phillip and his team who supported us during a transition period,” said David Stamler, M.D., Chief Executive Officer of Alterity.
Ms Macnish Niven has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minett. Ms Macnish Niven consults to a range of listed and unlisted companies in governance, finance and corporate structure. Ms Macnish Niven holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia and is a Chartered Finance Analyst.
Ms Macnish Niven will replace Mr Phillip Hains, who supported Alterity as CFO from December 2023. Mr Hains continues as Company Secretary.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ
Who is the new CFO of Alterity Therapeutics (ATHE)?
What is Abby Macnish Niven's background before joining Alterity Therapeutics (ATHE)?
When did Abby Macnish Niven start as CFO of Alterity Therapeutics (ATHE)?
Who did Abby Macnish Niven replace as CFO at Alterity Therapeutics (ATHE)?
